JW PHARMACEUTICAL
Financials
Valuation Metrics
JW PHARMACEUTICAL's Market Cap is ₩6701B. At end of 2025 it was ₩6166B. Ranked #389 of 2,421 in KR market (top 16%), #256 of 781 on KOSPI (top 33%), #44 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 670.12B KRW | KR#389/2,421 Sec#44/231 |
| Revenue | 820.86B KRW | KR#454/2,421 Sec#20/231 |
| Net Income | 101.28B KRW | KR#249/2,421 Sec#13/231 |
| Total Assets | 605.27B KRW | KR#677/2,421 Sec#37/231 |
| Net Assets | 369.37B KRW | KR#631/2,421 Sec#40/231 |
| Employees | 1,107 | KR#239/2,421 Sec#14/231 |
| Value | ||
| P/E | 6.62x | KR#521/2,421 Sec#22/231 |
| P/B | 1.81x | KR#1,879/2,421 Sec#138/231 |
| PEG | 0.07x | KR#356/2,421 Sec#19/231 |
| P/S | 0.82x | KR#1,254/2,421 Sec#71/231 |
| EV/EBITDA | 5.80x | KR#293/2,421 Sec#6/231 |
| FCF Yield | 12.63% | KR#516/2,421 Sec#16/231 |
| Profitability | ||
| ROE | 27.42% | KR#75/2,421 Sec#6/231 |
| ROA | 16.73% | KR#81/2,421 Sec#7/231 |
| Op. Margin | 13.94% | KR#333/2,421 Sec#31/231 |
| Revenue Growth | 10.50% | KR#877/2,421 Sec#84/231 |
| Earnings Growth | 94.60% | KR#407/2,421 Sec#29/231 |
| Financial Health | ||
| Debt Ratio | 63.87% | KR#1,141/2,421 Sec#134/231 |
| Total Debt | 32.10B KRW | KR#1,193/2,421 Sec#89/231 |
| FCF | 84.62B KRW | KR#219/2,421 Sec#13/231 |
| Cash | 39.23B KRW | KR#864/2,421 Sec#55/231 |
| Current Ratio | 1.56x | KR#1,147/2,421 Sec#124/231 |
| Net Debt/EBITDA | -0.06x | KR#590/2,421 Sec#36/231 |
| Dividend | ||
| Div. Yield | 2.34% | KR#796/2,421 Sec#40/231 |
| Div. Growth | 44.44% | KR#272/2,421 Sec#12/231 |
| Performance | ||
| 1Y Return | 26.41% | KR#382/2,421 Sec#24/231 |
| 1M Return | 5.66% | KR#705/2,421 Sec#48/231 |
| From 52W High | -28.66% | KR#491/2,421 Sec#28/231 |
| 1Y MDD | -43.66% | KR#716/2,421 Sec#56/231 |
| Trading | ||
| Volume | 39,344 shares | KR#1,247/2,421 Sec#122/231 |
| Trading Value | 1.10B KRW | KR#693/2,421 Sec#70/231 |
| Foreign Own. | 7.34% | KR#608/2,421 Sec#51/231 |
| Per Share | ||
| EPS | 4,232 KRW | KR#249/2,421 Sec#15/231 |
| BPS | 15,434 KRW | KR#682/2,421 Sec#45/231 |
Company Info
The company began as Joseon Choongwae Pharmaceutical Laboratory in 1945, incorporated in 1953, and expanded its business in 2019 by acquiring Vietnamese Euvipharm after listing in 1976. It holds products such as Livalo, Hemlibra, Trupass, Actemra, and the 3rd-generation 3-chamber nutritional infusion Winuf. The company leads the market with its combined novel drug of pitavastatin and ezetimibe. Utilizing the JWAVE platform, it applies AI models across the entire new drug development cycle to reduce time and cost. JW Pharmaceutical is headquartered in Gwacheon, Gyeonggi-do.